Your search for tofacitinib returned 114 results

The FDA has accepted Pfizer’s sNDA for review for an expanded indication for Xeljanz to include inhibition of progression of structural damage in the label. Xeljanz is a first in its class Janus Kinase inhibitor.

A comparative list of treatment options for arthritis including DMARDS and other immune modulators.

Pfizer announced that the FDA has approved Xeljanz (tofacitinib citrate) tablets for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) who have had inadequate response or intolerance to methotrexate.

This patient information fact sheet provides information on the definition, symptoms, causes, diagnostic tests, treatments and self-help measures for rheumatoid arthritis.